Completed PHASE1 INTERVENTIONAL NCT00785668

A Phase 1 Safety and Pharmacokinetics Study of AER 001 Administered as a Dry Powder in Asthmatic Subjects

Sponsor: Aerovance, Inc.

Conditions Asthma

Interventions AER 001

Updated 5 times since 2017 Last updated: Nov 4, 2008 Started: Nov 30, 2007 Completion: Feb 29, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Asthma, this trial is completed. The trial is conducted by Aerovance, Inc. and has accumulated 5 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aerovance, Inc.

Data source: Aerovance, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom